Compare Citius Pharmaceuticals Inc (CTXR) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Dollar Tree, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Dollar Tree, Inc. trades at $118.61 (market cap $22.26B). The key difference: Dollar Tree, Inc. is far larger — about 1634.4× Citius Pharmaceuticals Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Dollar Tree, Inc. for 58 Days on average.
| CTXR | DLTR | |
|---|---|---|
Market Cap | $13.62M | $22.26B |
Volume | 132,438 | 2,317,428 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $141.21 |
52-Week Low | $0.48 | $86.80 |
Typical Hold Time | 16 Days | 58 Days |
Enterprise Value | $3.79M | $28.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Dollar Tree (DLTR) trades at $116.30, up 0.09% with a bullish technical signal despite bearish moving averages. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $2.70 beating expectations of $1.15. Revenue trends show recovery from 2025's $17.58B to projected $20.1B in 2026, while net income rebounds from -$3.03B to projected $1.6B. Analyst consensus is bullish with 53% buy ratings and $139.33 price target, representing 20% upside potential.
DLTR presents a compelling investment case with improving fundamentals and positive earnings momentum, though margin pressures and tariff volatility remain key risks. The stock's attractive valuation (P/E 14.54, EV/EBITDA 9.91) combined with strategic initiatives and store expansions support growth outlook, but investors should monitor cost inflation and competitive pressures in the discount retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
